Quarterly ResultAug 6, 2026, 04:14 PM
Intellia Therapeutics Lonvo-z Phase 3 Positive; H1 2027 Launch Planned
AI Summary
Intellia Therapeutics reported positive topline data from its Phase 3 HAELO clinical trial for lonvo-z in hereditary angioedema (HAE) in April 2026, with a planned commercial launch in the first half of 2027, if approved. For the second quarter of 2026, the company's net loss increased to $(106.6) million, and collaboration revenue decreased to $7.7 million. The company strengthened its liquidity with $229.7 million in net cash from financing activities in the first half of 2026, including a $194.6 million follow-on public offering, and expects current cash to fund operations for at least 12 months.
Key Highlights
- Positive topline data from Phase 3 HAELO trial for lonvo-z (HAE) reported in April 2026.
- Planned commercial launch of lonvo-z in H1 2027, pending regulatory approval.
- Q2 2026 net loss increased to $(106.6) million from $(101.3) million in Q2 2025.
- Q2 2026 collaboration revenue decreased to $7.7 million from $14.2 million in Q2 2025.
- Net cash from financing activities was $229.7 million in H1 2026, including a $194.6 million follow-on offering.
- Cash, cash equivalents, and marketable securities totaled $522.2 million as of June 30, 2026.
- Stockholder lawsuit (Gonzalez v. Intellia Therapeutics, Inc.) dismissed on June 18, 2026.
- New Tech Square Lease for 125,000 sq ft in Cambridge commences Q3 2026.
Price Impact
More from NTLA